PHD Biosciences is developing a library of targeted small molecule anti-cancer therapeutics that selectively disrupt the epigenetic development of cancerous cells causing suppression of primary tumors and dramatic regression of established tumors. This novel approach originated in the laboratory of Professor Vern Schramm at the Albert Einstein College of Medicine, and PHD Biosciences is developing the lead molecules for anti-cancer indications. This project is currently supported by a Phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute, an Avon Foundation for Women award, and three New York State Center for Advanced Technology awards.
View Top Employees from Phd Biosciences| Website | http://phdbiosciences.com |
| Revenue | $6.1 million |
| Employees | 4 (0 on RocketReach) |
| Address | 180 Varick St Ste 526, New York, New York 10014, US |
| Phone | (646) 801-3872 |
| Industry | Business Services General, Business Services |
| Competitors | Biotech Primer, Cellectar Biosciences, Inc., Revitope, Tempest Therapeutics, Translational Drug Development (TD2) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies |
Looking for a particular Phd Biosciences employee's phone or email?
Phd Biosciences Questions
The Phd Biosciences annual revenue was $6.1 million in 2024.
Phd Biosciences is based in New York, New York.
The NAICS codes for Phd Biosciences are [541714, 54, 541, 54171, 5417].
The SIC codes for Phd Biosciences are [87, 873].
